Authors
Xirui He, Ruoshi Tian, Xufei Chen, Jiaqing Hu, Qiulian Zeng, Yao Xiao, Yan Yang
Published in
The Journal of pharmacy and pharmacology. Volume 78. Issue 9. Sep 01, 2026.
Abstract
To evaluate therapeutic mechanism of Gastrodia elata Blume and Acorus tatarinowii Schott (GEAT) herb pair in the treatment of epilepsy.
The anti-seizure effects were evaluated using the maximal electroshock (MES) and pentylenetetrazole (PTZ)-induced acute and kindling seizures. Seizure behaviors and electroencephalography (EEG) activity were assessed. Cognitive function, hippocampal pathology, ultrastructure and key targets NLRP3, caspase-8 and BDNF were also examined. Additionally, network pharmacology and molecular docking analyses were integrated to complement the experimental findings.
GEAT reduced the generalized seizures in the MES model. In the PTZ model, GEAT decreased the seizure stages, prolonged the latent period of epileptic seizures, and decreased the death rate. In the chronic PTZ model, GEAT significantly reduced the Racine score during the kindling process, suppressed spontaneous seizures and EEG abnormalities. It also effectively alleviated cognitive memory impairment and anxiety-like behavior. Furthermore, GEAT attenuated hippocampal neuronal loss, microglial and astrocytes activation and mitochondrial damage, and regulated BDNF, Caspase-8, NLRP3, Caspase-1 and IL-1β protein expression.
GEAT exerts multi-target effects against epilepsy, associated with synergistic regulation of glial activation, neuroinflammation, and apoptosis involving the NLRP3/caspase-1/IL-1β pathway, thereby providing a robust theoretical and experimental foundation for its clinical translation.
PMID:
42679235
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0